Related Experiment Video

Updated: Aug 7, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Obesity increases the risk for persisting obstructive sleep apnea after treatment in children

Louise M O'Brien1, Sinthu Sitha, Louise A Baur

  • 1Division of Pediatric Sleep Medicine and Kosair Children's Hospital Research Institute, Department of Pediatrics, University of Louisville, School of Medicine, 571 S. Preston Street Suite 321, Louisville, KY 40202, USA.

International Journal of Pediatric Otorhinolaryngology
|July 6, 2006
PubMed

Insights

Childhood obesity significantly increases the risk of persistent obstructive sleep apnea (OSA) after adenotonsillectomy. Obese children are more likely to have ongoing OSA symptoms post-treatment.

Area of Science:

  • Pediatric Pulmonology
  • Sleep Medicine
  • Obesity Research

Background:

  • Obstructive sleep apnea (OSA) is a common condition in children.
  • Obesity is a known risk factor for OSA, but its impact on treatment outcomes requires further evaluation.

Purpose of the Study:

  • To assess how obesity at diagnosis affects treatment success in pediatric obstructive sleep apnea (OSA).

Main Methods:

  • Retrospective analysis of 69 children with diagnostic and follow-up polysomnography data.
  • Obesity defined as BMI z-score > 2; OSA defined as respiratory disturbance index (RDI) >= 5.
  • Outcomes assessed post-adenotonsillectomy.

Main Results:

  • Obese children had significantly higher post-treatment RDI compared to non-obese children (10.7 vs. 3.7, p=0.01).
  • Disease resolution rates were lower in obese children (45%) versus non-obese (77.5%, p=0.011).
  • Obesity was associated with a 4.2-fold increased odds of persistent OSA post-treatment (adjusted OR 3.7, p=0.016).

Conclusions:

  • Childhood obesity at diagnosis is a significant predictor of persistent OSA after adenotonsillectomy.
  • This risk persists irrespective of the initial severity of OSA.
  • Weight management may be crucial for improving treatment outcomes in obese children with OSA.
Abstract

More Related Videos

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea07:54

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

Related Concept Videos

Sleep Apnea01:21

Sleep Apnea

Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.